Cart
sales@molnova.com
N-Acetyl-D-galactosamine
CAS No. 1811-31-0
N-Acetyl-D-galactosamine( D-GalNAc )
Catalog No. M19572 CAS No. 1811-31-0
Acetylgalactosamine is an important constituent of brain heteropolysaccharides (glycoproteins).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 43 | In Stock |
|
| 50MG | 29 | In Stock |
|
| 100MG | 38 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 84 | In Stock |
|
| 1G | 119 | In Stock |
|
Biological Information
-
Product NameN-Acetyl-D-galactosamine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAcetylgalactosamine is an important constituent of brain heteropolysaccharides (glycoproteins).
-
DescriptionAcetylgalactosamine is an important constituent of brain heteropolysaccharides (glycoproteins).
-
In Vitro——
-
In Vivo——
-
SynonymsD-GalNAc
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1811-31-0
-
Formula Weight221.21
-
Molecular FormulaC8H15NO6
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mazany KD et al. Human chondroitin 6-sulfotransferase: cloning gene structure and chromosomal localization. Biochim Biophys Acta. 1998 Jul 1;1407(1):92-7.
molnova catalog
related products
-
2-Phthalimidehydroxy...
2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Polatuzumab
Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.
-
Methoxychlor
Methoxychlor an organochlorine pesticide is thought to be an endocrine disrupter that affects Ca2? homeostasis and cell viability in different cell models.
